BMRN | tickerfilter.com

Fundamental analysis

26%

Profitability 20%

Dept financing 9%

Liquidity 69%

Performance 27%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.04%

1 Month

-0.29%

3 Months

-4.48%

6 Months

2.34%

1 Year

-11.19%

2 Year

-38.97%

Key data

Stock price

$54.62

P/E Ratio

32.72

DAY RANGE

$54.00 - $55.14

EPS

$1.82

52 WEEK RANGE

$50.76 - $66.28

52 WEEK CHANGE

-$11.82

MARKET CAP

11.417 B

YIELD

N/A

SHARES OUTSTANDING

192.323 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-04-2025

BETA

-0.01

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,546,035

AVERAGE 30 VOLUME

$1,617,286

Company detail

CEO: Jean-Jacques Bienaimé
Region: US
Website: biomarin.com
Employees: 3,080
IPO year: 1999

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

BMRN - BIOMARIN PHARMACEUTICAL INC